Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2061-2067

  Andre, Fabrice ^a,b   Hatzis, Christos ^c   Anderson, Keith ^b   Sotiriou, Christos ^d   Mazouni, Chafika ^b   Mejia, Jaime ^b   Wang, Bailiang ^b   Hortobagyi, Gabriel N ^b   Symmans, W Fraser ^b   Pusztai, Lajos ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Nuvera Biosciences   (United States)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MOLECULAR MARKER; PACLITAXEL; TAMOXIFEN; TAU PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TAU PROTEINS;

EID: 34247508923     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2078     Document Type: Article

References (17)

1. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
2. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
3. Symmans WF, Sotiriou C, Anderson SK, et al. Measurements of estrogen receptor and reporter genes from micro arrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. Breast Cancer Res Treat 2005;94:308a.
4. Ferreira A., Caceres A. Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules. J Neurosci 1991;11:392-400.
5. Lew GM. Changes in microtubular tau protein after estrogen in a cultured human neuroblastoma cell line. Gen Pharmacol 1993;24:1383-6.
6. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Research 2004;64:1522-33.
7. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
8. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
9. Hess KR, Anderson K, Symmans W, et al. Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2006;24:4236-44.
10. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
11. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67.
12. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.
13. Ma ZQ, Spreafico E, Pollio G, et al. Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci U S A 1993;90:3740-4.
14. Matsuno A, Takekoshi S, Sanno N, et al. Modulation of protein kinases and microtubule-associated proteins and changes in ultrastructure in female rat pituitary cells: effects of estrogen and bromocriptine. J Histochem Cytochem 1997;45:805-13.
15. Paik S, Shak S, Tang G, et al. A multi gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
16. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
17. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23:7332-41.